Genetic System's monoclonal technology
Executive Summary
Firm has produced a "panel of therapeutic antibodies" against antibiotic-resistant pseudomonas. The panel, developed with Cutter Biologicals, is expected to enter clinical trials soon, Genetic System's notes in its 1984 annual report. Genetic System and Cutler Biologicals are also developing a second panel of human monoclonal antibodies to combat four other gram-negative bacteria.